quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:30:00·2042d
PRRelease
Immunomedics, Inc. logo

Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

IMMU· Immunomedics, Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • IMMU
    Immunomedics, Inc.
    Health Care

Related

  • FDA515d
    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
  • PR739d
    NorthStar Appoints Peter Pfreundschuh to Board of Managers
  • FDA1175d
    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
  • FDA1418d
    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
  • FDA1836d
    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
  • FDA1842d
    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
  • FDA1842d
    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
  • 13D/G1892d
    SEC Form SC 13G/A filed
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022